Jason Wesley Christiansen

US Patent:

20130310267, Nov 21, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/841887

Inventors:

Mark D. GUSTAVSON - Greensboro NC, US
Jason CHRISTIANSEN - Carlsbad CA, US

International Classification:

G01N 33/68

US Classification:

506 9

Abstract:

The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.

US Patent:

20230104315, Apr 6, 2023

Filed:

Mar 25, 2021

Appl. No.:

17/907147

Inventors:

- San Diego CA, US
Jason CHRISTIANSEN - San Diego CA, US
Laurence JADIN - San Diego CA, US

International Classification:

C12Q 1/6886

Abstract:

Provided herein are methods and systems for detecting ecDNA positive cancers and methods and systems for developing signatures of ecDNA positive cancers.

US Patent:

20230078903, Mar 16, 2023

Filed:

Oct 21, 2022

Appl. No.:

18/048573

Inventors:

- San Diego CA, US
Ryan HANSEN - San Diego CA, US
Snezana MILUTINOVIC - San Diego CA, US
Jason CHRISTIANSEN - Carlsbad CA, US
Zachary HORNBY - San Diego CA, US
Sudhir CHOWDHRY - San Diego CA, US
Anthony CELESTE - San Diego CA, US
Kristen TURNER - San Diego CA, US
Deepti WILKINSON - San Diego CA, US

International Classification:

A61K 31/517
A61P 35/00
A61K 45/06

Abstract:

Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.

US Patent:

20190391164, Dec 26, 2019

Filed:

Sep 6, 2019

Appl. No.:

16/563757

Inventors:

- Basel, CH
Jason Christiansen - Carlsbad CA, US

Assignee:

Novartis AG - Basel

International Classification:

G01N 33/68
G01N 33/574
G01N 33/74

Abstract:

The present technology relates generally to determining a risk of recurrence of disease in a cancer patient. In particular, this approach to determining a risk of recurrence involves utilizing standardized quantitative assessments of the level of biomarker expression selected from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 (Ki67) in a patient's tumor to determine the risk of recurrence, thereby allowing a caretaker to determine the best course of treatment for the patient.